Skip to main content
Top
Published in: Inflammation 6/2013

01-12-2013

Serum Soluble Triggering Receptor on Myeloid Cells-1 (sTREM-1) is Elevated in Systemic Lupus Erythematosus but does not Distinguish Between Lupus Alone and Concurrent Infection

Authors: Yair Molad, Elisheva Pokroy-Shapira, Tania Kaptzan, Assaf Monselise, Michal Shalita-Chesner, Yehudit Monselise

Published in: Inflammation | Issue 6/2013

Login to get access

Abstract

We sought to determine serum triggering receptor expressed on myeloid cell-1 (sTREM-1) level in a cohort of patients with systemic lupus erythematosus (SLE). Serum sTREM-1 level of 98 patients with SLE and 49 healthy controls was assayed by ELISA. Serum sTREM-1 level was significantly elevated in a cohort of 78 unselected consecutively recruited patients with SLE (mean 1.1 ± 2.8 ρg/ml, median 0.02 ρg/ml) compared to that of the controls (mean 0.11 ± 0.3 ρg/ml, median 0 ρg/ml; p < 0.0001). We also determined serum sTREM-1 level of 20 SLE patients with a concurrent infection (mean 0.6 ± 1.1 ρg/ml, median 0.12 ρg/ml) and found it not statistically significant compared with that of the patients without infection. Serum sTREM-1 level did not correlate with SLE disease activity. Our finding of elevated serum sTREM-1 level suggests an increased shedding of TREM-1 in SLE and a possible novel pathway of innate immune response in autoimmunity.
Literature
1.
go back to reference Waldner, H. 2009. The role of innate immune responses in autoimmune disease development. Autoimmunity Reviews 8: 400–404.PubMedCrossRef Waldner, H. 2009. The role of innate immune responses in autoimmune disease development. Autoimmunity Reviews 8: 400–404.PubMedCrossRef
2.
go back to reference Tsokos, G.C. 2011. Systemic lupus erythematosus. The New England Journal of Medicine 365: 2110–2121.PubMedCrossRef Tsokos, G.C. 2011. Systemic lupus erythematosus. The New England Journal of Medicine 365: 2110–2121.PubMedCrossRef
3.
go back to reference Akira, S., S. Uematsu, and O. Takeuchi. 2006. Pathogen recognition and innate immunity. Cell 124(4): 783–801.PubMedCrossRef Akira, S., S. Uematsu, and O. Takeuchi. 2006. Pathogen recognition and innate immunity. Cell 124(4): 783–801.PubMedCrossRef
4.
go back to reference Rhee, J.W., K.W. Lee, W.J. Sohn, Y. Lee, O.H. Jeon, H.J. Kwon, and D.S. Kim. 2007. Regulation of matrix metalloproteinase-9 gene expression and cell migration by NF-kappa B in response to CpG-oligodeoxynucleotides in RAW 264.7 cells. Molecular Immunology 44(6): 1393–1400.PubMedCrossRef Rhee, J.W., K.W. Lee, W.J. Sohn, Y. Lee, O.H. Jeon, H.J. Kwon, and D.S. Kim. 2007. Regulation of matrix metalloproteinase-9 gene expression and cell migration by NF-kappa B in response to CpG-oligodeoxynucleotides in RAW 264.7 cells. Molecular Immunology 44(6): 1393–1400.PubMedCrossRef
5.
go back to reference Christensen, S.R., M. Kashgarian, L. Alexopoulou, R.A. Flavell, S. Akira, and M.J. Shlomchik. 2005. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. The Journal of Experimental Medicine 202: 321–331.PubMedCrossRef Christensen, S.R., M. Kashgarian, L. Alexopoulou, R.A. Flavell, S. Akira, and M.J. Shlomchik. 2005. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. The Journal of Experimental Medicine 202: 321–331.PubMedCrossRef
6.
go back to reference Christensen, S.R., J. Shupe, K. Nickerson, M. Kashgarian, R.A. Flavell, and M.J. Shlomchik. 2006. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 25: 417–428.PubMedCrossRef Christensen, S.R., J. Shupe, K. Nickerson, M. Kashgarian, R.A. Flavell, and M.J. Shlomchik. 2006. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 25: 417–428.PubMedCrossRef
7.
go back to reference Sato, Y., M. Miyata, T. Nishimaki, H. Kochi, and R. Kasukawa. 1999. CpG motif-containing DNA fragments from sera of patients with systemic lupus erythematosus proliferate mononuclear cells in vitro. Journal of Rheumatology 26: 294–301.PubMed Sato, Y., M. Miyata, T. Nishimaki, H. Kochi, and R. Kasukawa. 1999. CpG motif-containing DNA fragments from sera of patients with systemic lupus erythematosus proliferate mononuclear cells in vitro. Journal of Rheumatology 26: 294–301.PubMed
8.
go back to reference Richez, C., P. Blanco, I. Rifkin, J.F. Moreau, and T. Schaeverbeke. 2011. Role for toll-like receptors in autoimmune disease: the example of systemic lupus erythematosus. Joint, Bone, Spine 78: 124–130.PubMedCrossRef Richez, C., P. Blanco, I. Rifkin, J.F. Moreau, and T. Schaeverbeke. 2011. Role for toll-like receptors in autoimmune disease: the example of systemic lupus erythematosus. Joint, Bone, Spine 78: 124–130.PubMedCrossRef
9.
go back to reference Barrat, F.J., T. Meeker, J.H. Chan, C. Guiducci, and R.L. Coffman. 2007. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. European Journal of Immunology 37: 3582–3586.PubMedCrossRef Barrat, F.J., T. Meeker, J.H. Chan, C. Guiducci, and R.L. Coffman. 2007. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. European Journal of Immunology 37: 3582–3586.PubMedCrossRef
10.
go back to reference Tao, K., M. Fujii, S. Tsukumo, Y. Maekawa, K. Kishihara, Y. Kimoto, et al. 2007. Genetic variations of toll-like receptor 9 predispose to systemic lupus erythematosus in Japanese population. Annals of the Rheumatic Diseases 66: 905–909.PubMedCrossRef Tao, K., M. Fujii, S. Tsukumo, Y. Maekawa, K. Kishihara, Y. Kimoto, et al. 2007. Genetic variations of toll-like receptor 9 predispose to systemic lupus erythematosus in Japanese population. Annals of the Rheumatic Diseases 66: 905–909.PubMedCrossRef
11.
go back to reference Wu, O., G.P. Chen, H. Chen, X.P. Li, J.H. Xu, S.S. Zhao, et al. 2009. The expressions of toll-like receptor 9 and T-bet in circulating B and T cells in newly diagnosed, untreated systemic lupus erythematosus and correlations with disease activity and laboratory data in a Chinese population. Immunobiology 214: 392–402.PubMedCrossRef Wu, O., G.P. Chen, H. Chen, X.P. Li, J.H. Xu, S.S. Zhao, et al. 2009. The expressions of toll-like receptor 9 and T-bet in circulating B and T cells in newly diagnosed, untreated systemic lupus erythematosus and correlations with disease activity and laboratory data in a Chinese population. Immunobiology 214: 392–402.PubMedCrossRef
12.
go back to reference Bouchon, A., J. Dietrich, and M. Colonna. 2000. Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. Journal of Immunology 164: 4991–4995. Bouchon, A., J. Dietrich, and M. Colonna. 2000. Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. Journal of Immunology 164: 4991–4995.
13.
go back to reference Klesney-Tait, J., I.R. Turnbull, and M. Colonna. 2006. The TREM receptor family and signal integration. Nature Immunology 7: 1266–1273.PubMedCrossRef Klesney-Tait, J., I.R. Turnbull, and M. Colonna. 2006. The TREM receptor family and signal integration. Nature Immunology 7: 1266–1273.PubMedCrossRef
14.
go back to reference Sharif, O., and S. Knapp. 2008. From expression to signaling: roles of TREM-1 and TREM-2 in innate immunity and bacterial infection. Immunobiology 213(9–10): 701–713.PubMedCrossRef Sharif, O., and S. Knapp. 2008. From expression to signaling: roles of TREM-1 and TREM-2 in innate immunity and bacterial infection. Immunobiology 213(9–10): 701–713.PubMedCrossRef
15.
go back to reference Bouchon, A., F. Facchetti, M.A. Weigand, and M. Colonna. 2001. TREM-1 amplifies inflammation and is a crucial mediator of septic shock. Nature 410: 1103–1107.PubMedCrossRef Bouchon, A., F. Facchetti, M.A. Weigand, and M. Colonna. 2001. TREM-1 amplifies inflammation and is a crucial mediator of septic shock. Nature 410: 1103–1107.PubMedCrossRef
16.
go back to reference Gibot, S., F. Massin, P. Le Renard, et al. 2005. Surface and soluble triggering receptor expressed on myeloid cells-1: expression patterns in murine sepsis. Critical Care Medicine 33: 1787–1793.PubMedCrossRef Gibot, S., F. Massin, P. Le Renard, et al. 2005. Surface and soluble triggering receptor expressed on myeloid cells-1: expression patterns in murine sepsis. Critical Care Medicine 33: 1787–1793.PubMedCrossRef
17.
go back to reference Gibot, S., C. Buonsanti, F. Massin, M. Romano, M.N. Kolopp-Sarda, F. Benigni, G.C. Faure, M.C. Béné, P. Panina-Bordignon, N. Passini, and B. Lévy. 2006. Modulation of the triggering receptor expressed on the myeloid cell type 1 pathway in murine septic shock. Infection and Immunity 74(5): 2823–2830.PubMedCrossRef Gibot, S., C. Buonsanti, F. Massin, M. Romano, M.N. Kolopp-Sarda, F. Benigni, G.C. Faure, M.C. Béné, P. Panina-Bordignon, N. Passini, and B. Lévy. 2006. Modulation of the triggering receptor expressed on the myeloid cell type 1 pathway in murine septic shock. Infection and Immunity 74(5): 2823–2830.PubMedCrossRef
18.
go back to reference Kuai, J., B. Gregory, A. Hill, D.D. Pittman, J.L. Feldman, T. Brown, B. Carito, M. O'Toole, R. Ramsey, O. Adolfsson, K.M. Shields, K. Dower, J.P. Hall, Y. Kurdi, J.T. Beech, J. Nanchahal, M. Feldmann, B.M. Foxwell, F.M. Brennan, D.G. Winkler, and L.L. Lin. 2009. TREM-1 expression is increased in the synovium of rheumatoid arthritis patients and induces the expression of pro-inflammatory cytokines. Rheumatology (Oxford, England) 48(11): 1352–1358.CrossRef Kuai, J., B. Gregory, A. Hill, D.D. Pittman, J.L. Feldman, T. Brown, B. Carito, M. O'Toole, R. Ramsey, O. Adolfsson, K.M. Shields, K. Dower, J.P. Hall, Y. Kurdi, J.T. Beech, J. Nanchahal, M. Feldmann, B.M. Foxwell, F.M. Brennan, D.G. Winkler, and L.L. Lin. 2009. TREM-1 expression is increased in the synovium of rheumatoid arthritis patients and induces the expression of pro-inflammatory cytokines. Rheumatology (Oxford, England) 48(11): 1352–1358.CrossRef
19.
go back to reference Murakami, Y., T. Akahoshi, N. Aoki, M. Toyomoto, N. Miyasaka, and H. Kohsaka. 2009. Intervention of an inflammation amplifier, triggering receptor expressed on myeloid cells 1, for treatment of autoimmune arthritis. Arthritis and Rheumatism 60(6): 1615–1623.PubMedCrossRef Murakami, Y., T. Akahoshi, N. Aoki, M. Toyomoto, N. Miyasaka, and H. Kohsaka. 2009. Intervention of an inflammation amplifier, triggering receptor expressed on myeloid cells 1, for treatment of autoimmune arthritis. Arthritis and Rheumatism 60(6): 1615–1623.PubMedCrossRef
20.
go back to reference Molad Y, Pokroy-Shapira E, Carmon V. CpG-oligodeoxynucleotide-induced TLR9 activation regulates macrophage TREM-1 expression and shedding. Innate Immun. 2013. doi:10.1177/1753425913476970. Molad Y, Pokroy-Shapira E, Carmon V. CpG-oligodeoxynucleotide-induced TLR9 activation regulates macrophage TREM-1 expression and shedding. Innate Immun. 2013. doi:10.​1177/​1753425913476970​.
21.
go back to reference Tan, E.M., A.S. Cohen, J.F. Fries, et al. 1982. The 1982 revised criteria for classification of systemic lupus erythematosus. Arthritis and Rheumatism 25: 1271–1277.PubMedCrossRef Tan, E.M., A.S. Cohen, J.F. Fries, et al. 1982. The 1982 revised criteria for classification of systemic lupus erythematosus. Arthritis and Rheumatism 25: 1271–1277.PubMedCrossRef
22.
go back to reference Bombardier, C., D. Gladman, M.B. Urowitz, D. Caron, C.H. Chang, and the Committee on Prognosis Studies in SLE. 1992. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis and Rheumatism 35: 630–640.PubMedCrossRef Bombardier, C., D. Gladman, M.B. Urowitz, D. Caron, C.H. Chang, and the Committee on Prognosis Studies in SLE. 1992. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis and Rheumatism 35: 630–640.PubMedCrossRef
23.
go back to reference Gibot, S., M.N. Kolopp-Sarda, M.C. Bene, A. Cravoisy, B. Levy, G.C. Faure, and P.E. Bollaert. 2004. Plasma level of a triggering receptor expressed on myeloid cells-1: its diagnostic accuracy in patients with suspected sepsis. Annals of Internal Medicine 141(1): 9–15.PubMedCrossRef Gibot, S., M.N. Kolopp-Sarda, M.C. Bene, A. Cravoisy, B. Levy, G.C. Faure, and P.E. Bollaert. 2004. Plasma level of a triggering receptor expressed on myeloid cells-1: its diagnostic accuracy in patients with suspected sepsis. Annals of Internal Medicine 141(1): 9–15.PubMedCrossRef
24.
go back to reference Gibot, S., A. Cravoisy, B. Levy, M.C. Bene, G. Faure, and P.E. Bollaert. 2004. Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia. The New England Journal of Medicine 350(5): 451–458.PubMedCrossRef Gibot, S., A. Cravoisy, B. Levy, M.C. Bene, G. Faure, and P.E. Bollaert. 2004. Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia. The New England Journal of Medicine 350(5): 451–458.PubMedCrossRef
25.
go back to reference Determann, R.M., M. Weisfelt, J. de Gans, A. van der Ende, M.J. Schultz, and D. van de Beek. 2006. Soluble triggering receptor expressed on myeloid cells 1: a biomarker for bacterial meningitis. Intensive Care Medicine 32(8): 1243–1247.PubMedCrossRef Determann, R.M., M. Weisfelt, J. de Gans, A. van der Ende, M.J. Schultz, and D. van de Beek. 2006. Soluble triggering receptor expressed on myeloid cells 1: a biomarker for bacterial meningitis. Intensive Care Medicine 32(8): 1243–1247.PubMedCrossRef
26.
go back to reference Bishara, J., N. Hadari, M. Shalita-Chesner, Z. Samra, O. Ofir, M. Paul, N. Peled, S. Pitlik, and Y. Molad. 2007. Soluble triggering receptor expressed on myeloid cells-1 for distinguishing bacterial from aseptic meningitis in adults. European Journal of Clinical Microbiology and Infectious Diseases 26(9): 647–650.PubMedCrossRef Bishara, J., N. Hadari, M. Shalita-Chesner, Z. Samra, O. Ofir, M. Paul, N. Peled, S. Pitlik, and Y. Molad. 2007. Soluble triggering receptor expressed on myeloid cells-1 for distinguishing bacterial from aseptic meningitis in adults. European Journal of Clinical Microbiology and Infectious Diseases 26(9): 647–650.PubMedCrossRef
27.
go back to reference Determann, R.M., J.W. van Till, O. van Ruler, S.Q. van Veen, M.J. Schultz, and M.A. Boermeester. 2009. sTREM-1 is a potential useful biomarker for exclusion of ongoing infection in patients with secondary peritonitis. Cytokine 46(1): 36–42.PubMedCrossRef Determann, R.M., J.W. van Till, O. van Ruler, S.Q. van Veen, M.J. Schultz, and M.A. Boermeester. 2009. sTREM-1 is a potential useful biomarker for exclusion of ongoing infection in patients with secondary peritonitis. Cytokine 46(1): 36–42.PubMedCrossRef
28.
go back to reference Gibot, S., A. Cravoisy, M.N. Kolopp-Sarda, M.C. Bene, G. Faure, P.E. Bollaert, and B. Levy. 2005. Time-course of sTREM (soluble triggering receptor expressed on myeloid cells)-1, procalcitonin, and C-reactive protein plasma concentrations during sepsis. Critical Care Medicine 33(4): 792–796.PubMedCrossRef Gibot, S., A. Cravoisy, M.N. Kolopp-Sarda, M.C. Bene, G. Faure, P.E. Bollaert, and B. Levy. 2005. Time-course of sTREM (soluble triggering receptor expressed on myeloid cells)-1, procalcitonin, and C-reactive protein plasma concentrations during sepsis. Critical Care Medicine 33(4): 792–796.PubMedCrossRef
29.
go back to reference Su, L.X., L. Feng, J. Zhang, Y.J. Xiao, Y.H. Jia, P. Yan, D. Feng, and L.X. Xie. 2011. Diagnostic value of urine sTREM-1 for sepsis and relevant acute kidney injuries: a prospective study. Critical Care 15(5): R250.PubMedCrossRef Su, L.X., L. Feng, J. Zhang, Y.J. Xiao, Y.H. Jia, P. Yan, D. Feng, and L.X. Xie. 2011. Diagnostic value of urine sTREM-1 for sepsis and relevant acute kidney injuries: a prospective study. Critical Care 15(5): R250.PubMedCrossRef
30.
go back to reference Zhang, J., D. She, D. Feng, Y. Jia, and L. Xie. 2011. Dynamic changes of serum soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) reflect sepsis severity and can predict prognosis: a prospective study. BMC Infectious Diseases 11: 53.PubMedCrossRef Zhang, J., D. She, D. Feng, Y. Jia, and L. Xie. 2011. Dynamic changes of serum soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) reflect sepsis severity and can predict prognosis: a prospective study. BMC Infectious Diseases 11: 53.PubMedCrossRef
31.
go back to reference Collins, C.E., D.T. La, H.T. Yang, F. Massin, S. Gibot, G. Faure, and W. Stohl. 2009. Elevated synovial expression of triggering receptor expressed on myeloid cells 1in patients with septic arthritis or rheumatoid arthritis. Annals of the Rheumatic Diseases 68(11): 1768–1774.PubMedCrossRef Collins, C.E., D.T. La, H.T. Yang, F. Massin, S. Gibot, G. Faure, and W. Stohl. 2009. Elevated synovial expression of triggering receptor expressed on myeloid cells 1in patients with septic arthritis or rheumatoid arthritis. Annals of the Rheumatic Diseases 68(11): 1768–1774.PubMedCrossRef
32.
go back to reference Saurer, L., S. Rihs, M. Birrer, N. Saxer-Seculic, M. Radsak, C. Mueller, et al. 2012. Elevated levels of serum-soluble triggering receptor expressed on myeloid cells-1in patients with IBD do not correlate with intestinal TREM-1 mRNA expression and endoscopic disease activity. Journal of Crohn's & Colitis 6(9): 913–923.CrossRef Saurer, L., S. Rihs, M. Birrer, N. Saxer-Seculic, M. Radsak, C. Mueller, et al. 2012. Elevated levels of serum-soluble triggering receptor expressed on myeloid cells-1in patients with IBD do not correlate with intestinal TREM-1 mRNA expression and endoscopic disease activity. Journal of Crohn's & Colitis 6(9): 913–923.CrossRef
33.
go back to reference Kim, J., J.K. Koh, E.Y. Lee, J.A. Park, H.A. Kim, E.B. Lee, C. Garlanda, A. Cotena, and Y.W. Song. 2009. Serum levels of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) and pentraxin 3 (PTX3) as markers of infection in febrile patients with systemic lupus erythematosus. Clinical and Experimental Rheumatology 27: 773–778.PubMed Kim, J., J.K. Koh, E.Y. Lee, J.A. Park, H.A. Kim, E.B. Lee, C. Garlanda, A. Cotena, and Y.W. Song. 2009. Serum levels of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) and pentraxin 3 (PTX3) as markers of infection in febrile patients with systemic lupus erythematosus. Clinical and Experimental Rheumatology 27: 773–778.PubMed
34.
go back to reference Means, T.K., E. Latz, F. Hayashi, M.R. Murali, D.T. Golenbock, and A.D. Luster. 2005. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. The Journal of Clinical Investigation 115: 407–417.PubMed Means, T.K., E. Latz, F. Hayashi, M.R. Murali, D.T. Golenbock, and A.D. Luster. 2005. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. The Journal of Clinical Investigation 115: 407–417.PubMed
35.
go back to reference Papadimitraki, E.D., C. Choulaki, E. Koutala, G. Bertsias, C. Tsatsanis, I. Gergianaki, et al. 2006. Expansion of toll-like receptor 9-expressing B cells in active systemic lupus erythematosus: implications for the induction and maintenance of the autoimmune process. Arthritis and Rheumatism 54: 3601–3611.PubMedCrossRef Papadimitraki, E.D., C. Choulaki, E. Koutala, G. Bertsias, C. Tsatsanis, I. Gergianaki, et al. 2006. Expansion of toll-like receptor 9-expressing B cells in active systemic lupus erythematosus: implications for the induction and maintenance of the autoimmune process. Arthritis and Rheumatism 54: 3601–3611.PubMedCrossRef
Metadata
Title
Serum Soluble Triggering Receptor on Myeloid Cells-1 (sTREM-1) is Elevated in Systemic Lupus Erythematosus but does not Distinguish Between Lupus Alone and Concurrent Infection
Authors
Yair Molad
Elisheva Pokroy-Shapira
Tania Kaptzan
Assaf Monselise
Michal Shalita-Chesner
Yehudit Monselise
Publication date
01-12-2013
Publisher
Springer US
Published in
Inflammation / Issue 6/2013
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-013-9694-z

Other articles of this Issue 6/2013

Inflammation 6/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.